Analysts Set Insmed Incorporated (NASDAQ:INSM) Target Price at $91.60

Shares of Insmed Incorporated (NASDAQ:INSM) have been assigned an average rating of “Buy” from the sixteen ratings firms that are covering the stock, Marketbeat reports. Sixteen research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $91.60.

A number of equities research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research note on Friday, February 21st. Stifel Nicolaus dropped their price target on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research report on Friday, February 21st. Truist Financial increased their price target on shares of Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Morgan Stanley increased their price target on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Finally, Guggenheim reissued a “buy” rating and set a $101.00 price target on shares of Insmed in a research report on Tuesday, February 25th.

Insmed Price Performance

Shares of NASDAQ:INSM opened at $77.21 on Wednesday. Insmed has a one year low of $21.92 and a one year high of $84.91. The firm has a market capitalization of $13.97 billion, a price-to-earnings ratio of -13.81 and a beta of 1.11. The company’s fifty day moving average price is $75.32 and its 200-day moving average price is $73.81. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $104.44 million during the quarter, compared to analysts’ expectations of $102.31 million. On average, equities research analysts anticipate that Insmed will post -4.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Martina M.D. Flammer sold 6,172 shares of the stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $63.64, for a total value of $392,786.08. Following the completion of the transaction, the insider now directly owns 101,549 shares in the company, valued at $6,462,578.36. This trade represents a 5.73 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the completion of the transaction, the chief executive officer now owns 384,960 shares of the company’s stock, valued at approximately $26,885,606.40. The trade was a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 532,207 shares of company stock worth $41,400,465. 4.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Elequin Capital LP bought a new stake in Insmed during the 4th quarter valued at about $28,000. Steward Partners Investment Advisory LLC increased its stake in Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 163 shares in the last quarter. V Square Quantitative Management LLC increased its stake in Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 248 shares in the last quarter. Spire Wealth Management bought a new stake in Insmed during the 4th quarter valued at about $47,000. Finally, Smartleaf Asset Management LLC increased its stake in Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 411 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.